Morgan Stanley Bio Affinity Technologies, Inc. Transaction History
Morgan Stanley
- $1.36 Trillion
- Q1 2025
A detailed history of Morgan Stanley transactions in Bio Affinity Technologies, Inc. stock. As of the latest transaction made, Morgan Stanley holds 300 shares of BIAF stock, worth $84. This represents 0.0% of its overall portfolio holdings.
Number of Shares
300
Previous 500
40.0%
Holding current value
$84
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding BIAF
# of Institutions
18Shares Held
512KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA177KShares$49,5310.0% of portfolio
-
Geode Capital Management, LLC Boston, MA119KShares$33,2320.0% of portfolio
-
Sheaff Brock Investment Advisors, LLC53.7KShares$15,0450.0% of portfolio
-
Captrust Financial Advisors Raleigh, NC27.9KShares$7,8070.0% of portfolio
-
Warberg Asset Management LLC Winnetka, IL22.5KShares$6,3000.05% of portfolio
About bioAffinity Technologies, Inc.
- Ticker BIAF
- Exchange
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 2,727,580
- Market Cap $764K
- Description
- bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is b...